NoticeThis is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
a. Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), b. Primary cutaneous DLBCL leg type, c. Intravascular large B-cell lymphoma, d. EBV+ DLBCL NOS, e. HHV8+DLBCL NOS, f. primary mediastinal (thymic) large B-cell lymphoma, g. B-cell lymphoma, with intermediate features between DLBCL and classical Hodgkin lymphoma, h. follicular lymphoma grade 3B, i. high-grade B-cell lymphoma NOS, j. high-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements, k. T-cell/histiocyte-rich large B-cell lymphoma, l. DLBCL associated with chronic inflammation, m. ALK+ large B-cell lymphoma, n. large B-cell lymphoma with IRF4 rearrangement
1 total trials1 recruiting
Filter these 1 trials by phase, country, sponsor and more.